Research programme: cannabinoid therapeutics - Renew Biopharma
Latest Information Update: 28 Nov 2024
Price :
$50 *
At a glance
- Originator Renew Biopharma
- Class Analgesics; Anti-inflammatories; Cannabinoids; Phenols; Resorcinols; Small molecules
- Mechanism of Action Cannabinoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Inflammation; Pain
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for research development in Inflammation in USA
- 28 Nov 2024 No recent reports of development identified for research development in Pain in USA
- 16 Oct 2020 Renew Biopharma has patent protection for compositions and methods for using genetically modified enzymes in USA